Clinical trial OSE-279-C101
A multicenter, phase 1/2, dose-finding and dose expansion study of OSE-279, a PD-1 blocking monoclonal antibody, in subjects with advanced solid tumors or lymphomas (OSE-279-C101)
| Organ | Multiple |
|---|---|
| Trial status | Trial open for recruitment |
| Investigator | |
| Trial type |
Interventional with experimental drug
|
| Phase | Trial phase 1/2 |
| Academic trial | Non |
| Sponsor | OSE Immunotherapeutics |
| EudraCT Identifier | 2022-001136-28 |
| ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT05751798 |
| Last update |